--Eledon Pharmaceuticals, Inc. today announced that tegoprubart, the company’ s investigational anti-CD40L antibody, was used as a key component of the immunosuppression therapy regimen in a ...

Lead Product, QRX003, Being Tested in Two Active Registrational Clinical Studies for Netherton Syndrome Across the U.S., Europe, and the Middle East. QRX003 Peeling Skin Syndrome Clinical Program ...

Greenfield-based Elanco Health on Monday announced the $295 million cash sale of future U.S. royalty and milestone rights for the human use of a medication typically used for dogs and cats.

--BioArctic AB's partner Eisai today announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has reaffirmed its positive opinion for the anti-Aβ ...

Adial Pharmaceuticals strengthens its patent portfolio with the issuance of a new US patent covering AD04's potential for treating opioid use disorder through targeting the serotonin transporter gene.